Production (Stage)
Galectin Therapeutics Inc.
GALT
$1.34
$0.021.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.68M | 5.86M | 5.88M | 5.84M | 5.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.68M | 42.43M | 39.57M | 39.67M | 37.38M |
| Operating Income | -40.68M | -42.43M | -39.57M | -39.67M | -37.38M |
| Income Before Tax | -45.19M | -47.05M | -45.08M | -44.29M | -41.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.19 | -47.05 | -45.08 | -44.29 | -41.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.19M | -47.05M | -45.08M | -44.29M | -41.03M |
| EBIT | -40.68M | -42.43M | -39.57M | -39.67M | -37.38M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.72 | -0.76 | -0.73 | -0.78 | -0.74 |
| Normalized Basic EPS | -0.45 | -0.47 | -0.45 | -0.45 | -0.42 |
| EPS Diluted | -0.72 | -0.76 | -0.73 | -0.78 | -0.74 |
| Normalized Diluted EPS | -0.45 | -0.47 | -0.45 | -0.45 | -0.42 |
| Average Basic Shares Outstanding | 250.46M | 249.23M | 248.35M | 245.78M | 243.13M |
| Average Diluted Shares Outstanding | 250.46M | 249.23M | 248.35M | 245.78M | 243.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |